Eyestem
@EyestemResearch
Followers
400
Following
268
Media
13
Statuses
236
Developing allogeneic cell therapies for degenerative diseases of the eye
Bengaluru South, India
Joined September 2017
Delighted to announce our fund raise by existing investors and one major external investor. This funding enables us to complete our India phase 2 trial, file for the US IND and invest in follow on programs for incurable diseases https://t.co/EnPNWU7Q7g
mediabrief.com
Eyestem Research Pvt Ltd has raised $10 million in an oversubscribed round to advance its investigational retinal pigment epithelial therapy
1
0
2
Our CEO @jogin_desai will share trial results for Eyecyte-RPE™ at the Greater Bay Cell & Gene Therapy Forum on September 25/26 in Guangzhou. With 14.8 letter vision gain in 8 pts at 6 months with no SAEs, Eyestem is excited to begin Ph 2 trials in India this year/US next year.
0
0
4
Listen to our founder @jogin_desai share the story and science behind our journey on @CNBCTV18News with @Arundathi_Ram
.@EyestemResearch has raised $10M in an oversubscribed round to advance its retinal cell therapy, EyeCyte-RPE The Bengaluru- and Delaware-based biotech will use the funds for Phase 2 trials in India and a U.S. IND filing @Arundathi_Ram decodes the firm’s agenda with @jogin_desai
0
0
4
It is great to see the cell suspension approach being validated now through three independent projects by three fantastic teams. Reaffirms the solidity of the science @EyestemResearch
Congrats to Astellas for joining Lineage and Eyestem and showing that a suspension of lab-grown RPE cells can generate promising clinical outcomes in dryAMD patients. $LCTX
0
1
7
Delighted to announce completion of our phase 1 to treat Geographic Atrophy. Excellent safety profile with no serious adverse events while delivering clinically meaningful vision improvement-avg 15.8 letters in the first 6 pts over 6 mths. Onwards to Ph 2! https://t.co/kGP9hi8HRl
ophthalmologytimes.com
The trial treated 9 patients in 3 sequential, ascending dose-level (DL) cohorts.
0
0
2
Delighted to announce results for our trial to treat severe #DryAMD. Excellent safety profile with a strong, consistent efficacy is a good harbinger for our phase 2 in India/US @CCAMP_India
The trial, after receiving approval from the @CDSCO_INDIA_INF, was conducted across three reputed centres across India: @aiims_newdelhi, LV Prasad Eye Institute Hyderabad, and Shri Ganpati Nethralaya, Jalna. @EyestemResearch @jogin_desai @BattuRajani
https://t.co/3jCFZG22xr
0
0
2
Delighted to announce interim results for our phase 1 to treat Geographic Atrophy No Serious Adverse Events reported Average improvement of 14.9 letters in ETDRS over 3-6 m Anatomical changes identified in almost all pts at 3 months Will explore further in Ph 2 in India/US
0
1
12
Delighted to announce interim results for our FIH trial for treatment of GA 1. No SAEs and minimal TEAEs, 2. Five out of Six patients had a improvement in vision (3-31 letters). 3. Noticeable decrease in RPE/PR defect areas 4. Structural changes in OCT https://t.co/KdioXxskV3)
linkedin.com
We are delighted to announce interim results for our first in human trial for Geographic Atrophy secondary to Dry AMD. 1. Eyecyte-RPE was well tolerated across the first two doses with no serious...
0
2
8
Stoked to announce patent filing for our customized Sub-retinal injection technique to safely deliver Eyecyte-RPE in the area of interest for Geographic Atrophy .The invention harnesses readily available instruments and integrates them in a counter intuitive yet effective way!
0
0
6
Delighted to announce approval from our Drug Safety Monitoring Board (DSMB) to move forward with the second cohort of patients for our phase one trial to treat Geographic Atrophy secondary to Dry AMD
linkedin.com
We are delighted to announce approval from our Drug Safety Monitoring Board (DSMB) to move forward with the second cohort of patients for our phase one trial to treat Geographic Atrophy secondary to...
0
1
7
Huge increase in reagent cost post budget with prices going thru the roof bc of customs impact(19k to 51k!) Most startups cant qualify for the exemptions (valid DSIR/research inst. status). and cant survive this! Please help @FinMinIndia @AbleIndia @anand_bugworks @CCAMP_India
1
0
4
Catch an exciting talk by our chief scientist @RajarshiPal16 at the annual iPSC conference at @CSCR_CMC_Instem
Scientific Session on Application of iPSC Technology at the 9th Annual Cell and Gene Therapy Symposium on August 2, 2024 at 2:00 PM organized by @CSCR_CMC_inStem
#CGTS2024 #ipsctechnology #stemcelltherapy #genetherapy #celltherapy Register Now: https://t.co/VWgRRxCDcJ
0
0
1
Learn more about the progress of cell and gene therapy in India with clinical trials in eye disorder (Dry Age-related Macular Degeneration) and different hematological disorders. https://t.co/mRUpOjNi83
@EyestemResearch @jogin_desai @CSCR_CMC_inStem
isctglobal.org
Current Status of Cell & Gene Therapy in Dry Age-related Macular
0
2
7
Catch our founder and CEO @jogin_desai in conversation with @tweet2prashant on @ETNowSwadesh on the startup scene in India and the opportunities ahead. Today at 730 PM !
0
1
3
Grateful for the electrifying experience at ARVO in Seattle. Returned with a wealth of knowledge, amazing connections and renewed enthusiasm. Excited to put these learnings into action and drive our initiatives forward. Looking forward to the next one in Salt Lake City!!
#ARVO2024 in Seattle is a wrap! Thank you to all attendees, presenters/speakers and exhibitors from around the globe for making it such an amazing success. @ARVOinfo looks forward to seeing you in Salt Lake City, Utah for #ARVO2025. https://t.co/8fzfwlVvNU
1
2
20
So proud to see our Chief Scientist @RajarshiPal16 presenting our research on Oculo-cutaneous albinism at the prestigious Retinal Cell and Gene Therapy Innovation Summit in Seattle
1
1
19
Excited to speak at the "9th Retinal Cell and Gene Therapy Innovation Summit" in Seattle, Washington on 3rd May! https://t.co/2SeL21GquQ The founding team of @EyestemResearch will be at the upcoming @ARVOinfo with a poster on our recently approved Ph 1 study. @jogin_desai
1
4
16
Beyond thrilled to receive India approval to start first in human trials for Eyecyte-RPE to treat Dry AMD.
economictimes.indiatimes.com
Dry AMD, a leading cause of vision loss in the ageing population of people over 50, has long been a challenge due to the limited availability of effective treatments and the high costs associated...
1
2
13
Great news! 5 CCAMP portfolio startups are in India's top 10 bio startup shortlist by the amazing @bwmillionaires
https://t.co/zIsRvrPw95 Backstage with Billionaires revisited their 2020 shortlist spurred by Indian biotech's prolific growth from their 2020 estimated valuation
0
8
19
Excellent basic science work by scientists at @EyestemResearch on rare disease modelling
Happy to share our @EyestemResearch @BattuRajani new work on modelling oculocutaneous albinism type 1A published in the special issue of #JBiosci with @CCAMP_Bangalore @Taslimarif. Great effort by @JanaviSubramani and Niharika! https://t.co/0eDoQsLxiS
0
0
5